Advertise
NEWSLETTER
Jupiter Neurosciences doses...
Cerevance reports Solengepr...
AgelessRx introduces GHK-Cu...
ProMIS appoints new chief c...
Shift uses AI virtual cells...
Jupiter Neurosciences doses...
Cerevance reports Solengepr...
AgelessRx introduces GHK-Cu...
ProMIS appoints new chief c...
Shift uses AI virtual cells...
UNITY Biotech

Interviews of 2025: The innovators

Biotech lands $35m to combat cognitive decline with ‘longevity protein’

UNITY Bio lays off staff and seeks ‘strategic alternatives’

‘We’ve shown that targeting senescent cells can lead to improved outcomes’

UNITY Biotech reveals topline results from senolytic DME trial

New research supports therapeutic potential of senolytics in DME

New research supports therapeutic potential of senolytics in DME

Longevity investment bulletin: Insilico Medicine, Biophytis, Synartro and more

Longevity investment bulletin: Celularity, Biophytis, Longeveron and more

Getting comfortable with senotherapeutics

Getting comfortable with senotherapeutics

Longevity investment bulletin: Assured Allies, Fountain Life, Form Bio and more

Longevity investment bulletin: CARMAT, LifeX Ventures, Fractyl and more

The latest longevity science, investment, innovation and insight, delivered every morning.

Unlock Longevity Biotech Report for FREE

  • $617BN - Annual global revenue by 2045
  • $30BN+ - Invested in under 2 years
  • 3,036 - Therapeutics individually assessed